Cancer still dominates orphan drug approvals: Data Byte

At the half-year mark, about half of the orphan drugs approved by FDA have been for rare cancer indications, continuing the trend of previous years.

Orphan drug approvals in neurology, which has been the second or third most active disease area in prior years, have dropped to seventh place so far in 2021, tied with four other disease areas...